What this consultation may focus on.
Reviewing whether immunotherapy may be suitable
Understanding biomarker and molecular-test results
Assessing targeted treatment options
Monitoring treatment response
Recognising treatment-specific side effects early
Decisions made from the whole clinical picture.
Immunotherapy helps the immune system act against cancer, while targeted therapies are designed around particular molecules or pathways that can drive cancer growth. These treatments are not interchangeable and are not suitable for every cancer. Selection depends on diagnosis, stage, biomarkers, previous treatment and the individual clinical picture.
Common reasons patients seek an oncology review.
- Immunotherapy has been suggested
- A biopsy or molecular report shows a potentially actionable biomarker
- You want to understand how targeted therapy differs from chemotherapy
- New symptoms develop while receiving immune-based treatment
Questions patients often ask.
Is immunotherapy better than chemotherapy?
There is no single treatment that is best for every cancer. Immunotherapy may be useful in selected cancers and situations, while chemotherapy remains important for many diagnoses. Sometimes the treatments are combined.
Why are biomarker tests important?
Some targeted treatments and immunotherapies work best when a cancer has particular molecular features. Biomarker testing can help identify whether a specific treatment is relevant.
Are immunotherapy side effects different?
They can be. Because immunotherapy changes immune activity, it can sometimes cause inflammation in healthy organs. New or unusual symptoms should be reported promptly to the oncology team.